Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
10.92
Nov 20 • 3:59 PM ET Dollar change-0.25 Percentage change(-2.24%)
Aftermarket Close
10.92
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
99.28M
Enterprise Value
103.38M
Income
1.88M
Sales
33.21M
Book/sh
3.61
Cash/sh
0.87
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
73
IPO
May 05, 1987
P/E
54.11
Forward P/E
-
PEG
-
P/S
2.99
P/B
3.03
P/C
12.55
P/FCF
18.39
EV/EBITDA
20.80
EV/Sales
3.11
Quick Ratio
2.50
Current Ratio
4.61
Debt/Eq
0.37
LT Debt/Eq
0.32
Option/Short
No / Yes
EPS (ttm)
0.20
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
29.01% 4.06%
Sales past 3/5Y
14.19% 12.50%
EPS Y/Y TTM
-20.09%
Sales Y/Y TTM
19.59%
EPS Q/Q
764.94%
Sales Q/Q
46.02%
Insider Own
37.62%
Insider Trans
0.23%
Inst Own
17.93%
Inst Trans
7.23%
ROA
4.01%
ROE
6.01%
ROIC
4.34%
Gross Margin
40.83%
Oper. Margin
8.44%
Profit Margin
5.66%
SMA20
3.82%
SMA50
6.69%
SMA200
18.91%
Trades
Shs Outstand
9.09M
Shs Float
5.67M
52W High
12.10 -9.75%
52W Low
4.52 141.59%
Volatility
6.57% 3.77%
ATR (14)
0.46
RSI (14)
56.88
Beta
0.56
Rel Volume
1.30
Avg Volume
14.42K
Volume
18,759
Perf Week
1.58%
Perf Month
4.60%
Perf Quarter
10.98%
Perf Half Y
7.91%
Perf YTD
77.56%
Perf Year
137.39%
Perf 3Y
136.66%
Perf 5Y
23.53%
Perf 10Y
110.00%
Recom
-
Target Price
-
Prev Close
11.17
Price
10.92
Change %
-2.24%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
te Boekhorst Paul Francis OlivPresident and CEONov 12 '26Option Exercise6.1016,39399,99734,131Nov 16 01:54 PM
te Boekhorst Paul Francis OlivPresident and CEOJun 18 '26Buy9.498,00075,96017,785Jun 22 08:33 AM
BRIGHAM MICHAEL FDirectorMar 20 '26Option Exercise5.8425,000146,000229,752Mar 24 07:57 PM
te Boekhorst Paul Francis OlivPresident and CEODec 03 '25Buy5.026,07730,5369,785Dec 03 04:14 PM
te Boekhorst Paul Francis OlivPresident and CEODec 02 '25Buy4.873,70818,0533,708Dec 03 04:14 PM
Tomsche David ScottDirectorNov 25 '25Buy4.761,6337,7814,740Nov 28 08:12 AM
Tomsche David ScottDirectorNov 25 '25Buy4.761,6337,77352,720Nov 28 08:12 AM
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. It operates through the following segments: Scours and Mastitis. The Scours segment consists of the First Defense product line. The Mastitis segment includes the CMT product line consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. The company was founded in 1982 and is headquartered in Portland, ME.
PresidentMr. Paul F. Olivier Te Boekhorst
CFOMr. Timothy C. Fiori
Senior Vice President of Sales & MarketingMs. Bobbi Jo Brockmann
Director of Finance & Administration and ControllerMs. Elizabeth S. Toothaker
Senior Director of QualityMr. A. Gustavo Scaffa